利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

371 条记录 (耗时 0.024 秒)

    R-hydroxynefazodone
    32.
    发明申请
    R-hydroxynefazodone 失效
    R-羟基吗唑酮

    公开(公告)号：US20020052382A1

    公开(公告)日：2002-05-02

    申请号：US09988935

    申请日：2001-11-19

    申请人： Sepracor Inc.

    发明人： Timothy J. Barberich ,  Paul D. Rubin ,  William E. Yelle

    IPC分类号： A61K031/496

    CPC分类号： A61K31/496 ,  C07D249/12

    摘要： The R-isomer of the hydroxy metabolite of nefazodone, R-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. R-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.

    摘要翻译： 奈法唑酮的羟基代谢物的R-异构体R-羟基吗啡酮是抑制剂的有效治疗剂，其不会引起与奈法唑酮相关的不良反应。 R-羟基吗唑酮也可用于治疗偏头痛，恐慌症，创伤后应激障碍和睡眠障碍。

    Compositions of optically pure (+) norcisapride
    34.
    发明申请
    Compositions of optically pure (+) norcisapride 失效
    光学纯（+）诺西沙必利组合物

    公开(公告)号：US20010020031A1

    公开(公告)日：2001-09-06

    申请号：US09809165

    申请日：2001-03-16

    申请人： Sepracor Inc.

    发明人： John R. McCullough ,  Thomas P. Jerussi

    IPC分类号： A61K031/445

    CPC分类号： A61K31/495 ,  A61K31/4468 ,  A61K2300/00

    摘要： Compositons employing and methods utilizing the optically pure (null) isomer of norcisapride are disclosed. This compound has surprisingly been found to be a potent drug for the treatment of disorders of the central nervous system. The compound, (null) norcisapride, has also been found to be a potent antiemetic agent. Finally, the (null) isomer of norcisapride also avoids certain adverse side effects and certain adverse drug interactions.

    摘要翻译： 公开了使用诺西西滨的旋光纯（+）异构体的复合物和方法。 令人惊讶地发现，该化合物是用于治疗中枢神经系统疾病的有效药物。 化合物（+）诺西沙必利还被发现是一种有效的止吐剂。 最后，诺西沙必利的（+）异构体也避免了某些不良副作用和某些不良药物相互作用。

    Methods and compositions for treating allergic disorders and other disorders using metabolic derivatives of astemizole
    36.
    发明授权
    Methods and compositions for treating allergic disorders and other disorders using metabolic derivatives of astemizole 失效
    使用阿司咪唑的代谢衍生物治疗过敏性疾病和其他疾病的方法和组合物

    公开(公告)号：US6130233A

    公开(公告)日：2000-10-10

    申请号：US182685

    申请日：1994-01-18

    申请人： Raymond L. Woosley ,  A. K. Gunnar Aberg

    发明人： Raymond L. Woosley ,  A. K. Gunnar Aberg

    IPC分类号： C07D401/12 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/4523 ,  A61K31/454 ,  A61K45/00 ,  A61K45/06 ,  A61P3/08 ,  A61P3/10 ,  A61P11/00 ,  A61P11/02 ,  A61P11/06 ,  A61P31/12 ,  A61P37/08 ,  A61P43/00

    CPC分类号： A61K31/445 ,  A61K31/454

    摘要： Methods and compositions are disclosed utilizing metabolic derivatives of astemizole for the treatment of allergic disorders while avoiding the concomitant liability of adverse effects associated with the astemizole. The metabolic derivatives of astemizole are also useful for the treatment of retinopathy and other small vessel disorders associated with diabetes mellitus and such other conditions as may be related to the antihistamine activity of astemizole. For example, the metabolic derivatives of astemizole are useful for the treatment of asthma, motion sickness, and vertigo, without the concomitant liability of adverse effects associated with astemizole. Furthermore, the metabolic derivatives of astemizole, in combination with non-steroidal anti-inflammatory agents or other non-narcotic analgesics, or in combination with a decongestant, cough suppressant/antitussive or expectorant, are useful for the treatment of cough, cold, cold-like, and/or flu symptoms and the discomfort, headache, pain, fever, and general malaise associated therewith, without the concomitant liability of adverse effects associated with astemizole.

    摘要翻译： 公开了利用阿司咪唑的代谢衍生物治疗过敏性疾病的方法和组合物，同时避免与阿司咪唑相关的副作用的伴随的责任。 阿司咪唑的代谢衍生物也可用于治疗与糖尿病相关的视网膜病变和其它小血管障碍以及可能与阿司咪唑的抗组织胺活性相关的其它病症。 例如，阿司咪唑的代谢衍生物可用于治疗哮喘，晕车和眩晕，而不伴随与阿司咪唑有关的不良反应。 此外，阿司咪唑的代谢衍生物与非甾体抗炎剂或其他非麻醉止痛剂组合，或与减充血剂，止咳剂/镇咳药或祛痰剂组合可用于治疗咳嗽，感冒，感冒 类似，和/或流感症状以及与之相关的不适，头痛，疼痛，发烧和全身不适，而不伴随与阿司咪唑有关的不良反应。

    Methods for treating hypertension, and angina using optically pure (-) amlodipine
    37.
    发明授权
    Methods for treating hypertension, and angina using optically pure (-) amlodipine 失效
    使用光学纯（ - ）氨氯地平治疗高血压和心绞痛的方法

    公开(公告)号：US6057344A

    公开(公告)日：2000-05-02

    申请号：US334771

    申请日：1994-11-04

    申请人： James W. Young

    发明人： James W. Young

    IPC分类号： A61K31/44 ,  A61P9/00 ,  A61P9/12

    CPC分类号： A61K31/44 ,  Y10S514/866 ,  Y10S514/929

    摘要： Methods are disclosed utilizing the optically pure (-) isomer of amlodipine. This compound is a potent drug for the treatment of hypertension while avoiding the concomitant liability of adverse effects associated with the racemic mixture of amlodipine. The (-) isomer of amlodipine is also useful for the treatment of angina without the concomitant liability of adverse effects associated with the racemic mixture of amlodipine.

    摘要翻译： 公开利用氨氯地平的光学纯（ - ）异构体的方法。 该化合物是治疗高血压的有效药物，同时避免与氨氯地平外消旋混合物相关的副作用的伴随责任。 氨氯地平的（ - ）异构体也可用于治疗心绞痛，而不伴随氨氯地平外消旋混合物的副作用。

    Methods for treating behavioral and other disorders using optically pure R(+) ondansetron
    39.
    发明授权
    Methods for treating behavioral and other disorders using optically pure R(+) ondansetron 失效
    使用光学纯的R（+）昂丹司琼治疗行为和其他障碍的方法

    公开(公告)号：US5962494A

    公开(公告)日：1999-10-05

    申请号：US12428

    申请日：1998-01-23

    申请人： James W. Young

    发明人： James W. Young

    IPC分类号： A61K9/08 ,  A61K9/48 ,  A61K31/415 ,  A61K31/4178

    CPC分类号： A61K31/4178 ,  A61K31/415 ,  Y10S514/872

    摘要： Methods and compositions are disclosed utilizing the optically pure R(+) isomer of ondansetron. This compound is a potent drug for the treatment of nausea and vomiting associated with chemotherapy and radiation therapy, while avoiding the concomitant liability of adverse effects associated with the racemic mixture of ondansetron. The R(+) isomer of ondansetron is also useful for the treatment of behavioral disorders such as mood anxiety and schizophrenia, and such other conditions as may be related to R(+) ondansetron's activity as a competitive antagonist of serotonin receptor subtype 5-HT.sub.3 such as disorders of gastrointestinal motility, depression, migraine, and as an aid for alcohol withdrawal, nicotine withdrawal, and drug (benzodiazepine et al.) withdrawal, without the concomitant liability of adverse effects associated with the racemic mixture of ondansetron. Furthermore, the R(+) isomer of ondansetron is also useful for the treatment of cognitive disorders such as dementia or age-associated memory impairment, while avoiding the concomitant liability of adverse effects associated with the racemic mixture of ondansetron.

    摘要翻译： 公开了使用昂丹司琼的光学纯的R（+）异构体的方法和组合物。 该化合物是用于治疗与化疗和放射治疗相关的恶心和呕吐的有效药物，同时避免与昂丹司琼外消旋混合物相关的副作用的伴随责任。 昂丹司琼的R（+）异构体也可用于治疗诸如情绪焦虑和精神分裂症等行为障碍，以及可能与R（+）昂丹司琼活性相关的其他条件，作为5-羟色胺受体亚型5-HT3的竞争性拮抗剂 例如消化道运动障碍，抑郁症，偏头痛，以及用于酒精戒断，尼古丁戒断和药物（苯并二氮杂类等）撤离的辅助，而不伴随昂丹司琼外消旋混合物的不良反应。 此外，昂丹司琼的R（+）异构体也可用于治疗诸如痴呆或年龄相关记忆障碍的认知障碍，同时避免与昂丹司琼的外消旋混合物相关的副作用的伴随责任。

    Methods for treating gastrointestinal motility dysfunction using optically pure (+) cisapride
    40.
    发明授权
    Methods for treating gastrointestinal motility dysfunction using optically pure (+) cisapride 失效
    使用光学纯（+）西沙必利治疗胃肠蠕动功能障碍的方法

    公开(公告)号：US5955478A

    公开(公告)日：1999-09-21

    申请号：US754657

    申请日：1996-11-21

    申请人： Nancy M. Gray ,  James W. Young

    发明人： Nancy M. Gray ,  James W. Young

    IPC分类号： C07D211/62 ,  A61K31/445 ,  A61K31/4468 ,  A61P1/00 ,  A61P1/08 ,  A61P1/10 ,  A61P1/14

    CPC分类号： A61K31/445 ,  A61K31/4468

    摘要： Methods are disclosed utilizing the optically pure (+) isomer of cisapride. The optically pure (+) isomer of cisapride is useful for the treatment of dyspepsia and such other conditions as may be related to the activity of (+) cisapride as a prokinetic agent, such as gastroparesis, constipation, post-operative operative ileus, and intestinal pseudo-obstruction, without the concomitant liability of adverse effects associated with the racemic mixture of cisapride. The (+) isomer of cisapride also exhibits longer duration of action than does racemic cisapride and is useful for treatment of disorders of the central nervous system.

    摘要翻译： 公开利用西沙必利的光学纯（+）异构体的方法。 西沙必利的光学纯（+）异构体可用于治疗消化不良和其他可能与（+）西沙必利作为促动力剂的活性相关的其它病症，如胃轻瘫，便秘，手术后肠梗阻和 肠假性梗阻，没有与西沙必利的外消旋混合物相关的副作用的伴随的责任。 西沙必利的（+）异构体也表现出比外消旋西沙必利更长的作用时间，并且可用于治疗中枢神经系统疾病。